MedPath

KITE PHARMA, INC.

KITE PHARMA, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
2009-01-01
Employees
1K
Market Cap
-
Website
http://www.kitepharma.com

CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility

A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility.

© Copyright 2025. All Rights Reserved by MedPath